Navigation Links
Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives
Date:12/3/2008

utical partners for our ZFP Therapeutic programs."

Sangamo Accomplishments in 2008

During the briefing several of the company's achievements will be highlighted including:

Clinical

-- Presentation of the full data set from single dose Phase 1b study (SB-509-401) of SB-509 in subjects with diabetic neuropathy (DN) demonstrating that the drug is well-tolerated and statistically and clinically significant improvements in measures of nerve health at 180 days post treatment.

-- Initiation of repeat dosing Phase 2 clinical trials of SB-509 in stem cell mobilization (SB-509-703) and ALS (SB-509-801).

-- Completion of enrollment and expansion of Phase 2 clinical trial in subjects with moderate to severe DN (SB-509-701). Presentation of encouraging positive interim data from this trial.

-- Presentation of top line Phase 2 data from repeat dosing study of SB-509 in mild to moderate DN (SB-509-601) demonstrating that the drug is well-tolerated in a repeat-dosing setting; however, no significant differences were observed in improvement in measures of nerve health between placebo and treated subjects at primary evaluation point 180 days post treatment. Analysis of these data is ongoing.

Business

-- Dow AgroSciences announces early exercise of an option for a commercial license for ZFP technology in plant agriculture.

-- Official launch of Sigma-Aldrich CompoZr platform of zinc finger nuclease (ZFN) reagents for gene-editing.

-- Entry into Research and License Agreement with Genentech, Inc. for cell line engineering and License Agreement with Open Monoclonal Technologies (OMT) and Roche for transgenic animal generation.

Financial

-- Sangamo updated guidance on its expectations of 2008 year end cash to $60M in cash and cash equivalents, which the company believes is sufficient to fund
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
2. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
3. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
7. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BOSTON , Sept. 16, 2014 QPID ... a move to new headquarters in Boston ... The new headquarters will be at 175 Franklin Street in ... operations and marketing teams. QPID Health,s new Southern ... Parkway in Carlsbad.  The expansion will help meet the demands ...
(Date:9/16/2014)... , Sept. 16, 2014  Decision Resources Group finds that the ... billion in 2013 to over $18.2 billion in 2023 in ... Germany , Italy , ... and Japan . TNF-alpha inhibitors will remain the ... RA market, but growth will be constrained and patient shares will ...
(Date:9/16/2014)... 2014  Formex, LLC ("Formex"), a leader in ... Weilersbacher joined Formex as Director of Quality ... Greg Weilersbacher has over 20 ... in Quality Assurance, Facility Validation, GMP manufacturing, and ... to Formex a diverse wealth of experience. ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
(Date:9/16/2014)... September 16, 2014 Who:, The Pulmonary ... Medical Campus and Children’s Hospital Colorado are ... the country’s leading pulmonary hypertension association that works to find ... disease of the lungs that affects the functioning of the ... mean survivability is only 2.8 years. , What:, Colorado ...
(Date:9/16/2014)... September 16, 2014 As part of ... Latin American Citizens (LULAC) will host the second annual ... Salud will feature free health screenings for osteoporosis, HIV, ... includes glucose and cholesterol levels as well as bone ... for children under 6 years old , The event ...
(Date:9/16/2014)... 16, 2014 (HealthDay News) -- Including women older than ... to a sharp reduction in advanced forms of the ... breast cancer screening programs could result in older women ... So, the decision to screen older women for breast ... recommended. "Instead of using mass screening, the decision ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. ... cancer survivors are alive today, compared to just 3 ... reported Tuesday. These individuals amount to 4 percent ... childhood cancer, according to the association,s annual progress report. ... treatment of cancer and details some of the challenges ...
(Date:9/16/2014)... for Radiation Oncology (ASTRO) has selected C.M. Charlie Ma, ... Oncology, and Director of Medical Physics at Fox ... The distinguished members selected to receive the Fellow of ... on Tuesday, September 16, at the ASTRO,s 56th Annual ... Fellows designation is a great honor and we are ...
Breaking Medicine News(10 mins):Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2Health News:Some Benefits of Screening Elderly Women for Breast Cancer Questioned 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4
... A new UC Irvine study finds that lithium chloride, ... the development of inclusion body myositis, a skeletal muscle ... by scientists Frank LaFerla and Masashi Kitazawa, mice genetically ... six months after receiving daily doses of lithium chloride, ...
... Go,Healthcare, Inc. (OTC Bulletin Board: OGOH; ,OTG, ,the ... integrator,announced today that after more than four industry ... Value Added Reseller (,VAR,),business unit to Tampa, FL ... of the sale, in the amount of $4 ...
... to scenic attractions, COLUMBIA, S.C., March 18 ... Costa Rica for care now have a convenient ... farms, biological reserves,and other breathtaking scenery while awaiting ... division of Columbia, S.C.-based Companion,Global Healthcare Inc., has ...
... study appearing in the March 2008 issue of the ... natural family planning method developed by researchers from Georgetown ... women to family planning. More than half the women ... used family planning and on average, contraceptive use increased ...
... DALLAS, March 18 Phoenix Health Systems, a ... on the,business goals of healthcare organizations, announced today ... Management Services, Inc.,(TMSI) has awarded Phoenix Health Systems, ... TMSI performs considerable due diligence to,make certain the ...
... N.J., March 18 Barr,Pharmaceuticals, Inc. (NYSE: ... (LSE: PLVD), sent Notice to Deutsche Bank, acting ... Deposit Agreement (the "Deposit,Agreement") effective June 19, 2008 ... PLIVA will seek to delist from the London,Stock ...
Cached Medicine News:Health News:Lithium chloride slows onset of skeletal muscle disorder 2Health News:Lithium chloride slows onset of skeletal muscle disorder 3Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 3Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 4Health News:Companion Global Dental Clients Have New Reason to Smile in Costa Rica 2Health News:New choices bring wider range of women to family planning 2Health News:Texas Organization of Rural and Community Hospitals (TORCH) Awards Phoenix Health Systems Endorsed Vendor Status 2Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 2Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 3Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 4
Ungrooved permanent silicone strip. Indications: For trapdoor procedure. Overall length: 125 mm, 4.9 inches....
Ungrooved permanent silicone strip. Indications: For trapdoor procedure. Overall length: 125 mm, 4.9 inches....
Used with Double Tantalum Clip (250 style) E5381 852. Overall length: 7.0 mm....
Concave inner surface to conform to the globe. Indications: Wide scleral bed. Outside diameter 32 mm....
Medicine Products: